Telescope Innovations Presents Results of First Fiscal Quarter 2025
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) reported Q1 FY2025 financial results with revenues of $1.2 million, down from $1.5 million in Q1 FY2024. The company recorded an adjusted EBITA loss of $103,177, compared to earnings of $505,171 in the same period last year. Expenses increased to $1.5 million from $1.3 million year-over-year.
Key operational highlights include successful delivery of DirectInject-LC™ products under the Mettler Toledo distribution agreement, with product demonstrations across multiple countries. The company advanced its Self-Driving Labs research with Pfizer, achieving Certified Systems Integrator status for Universal Robots systems. Additionally, Telescope demonstrated production of >99.5% pure lithium carbonate using its ReCRFT™ technology and is building a pilot plant in Vancouver for scale-up studies.
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) ha riportato i risultati finanziari del Q1 FY2025 con ricavi di $1,2 milioni, in calo rispetto ai $1,5 milioni del Q1 FY2024. L'azienda ha registrato una perdita di EBITA rettificata di $103,177, rispetto agli utili di $505,171 nello stesso periodo dell'anno scorso. Le spese sono aumentate a $1,5 milioni rispetto ai $1,3 milioni dell'anno precedente.
Tra i principali punti salienti operativi ci sono la consegna riuscita dei prodotti DirectInject-LC™ nell'ambito dell'accordo di distribuzione con Mettler Toledo, con dimostrazioni dei prodotti in diversi paesi. L'azienda ha fatto progressi nella ricerca dei Self-Driving Labs con Pfizer, ottenendo lo status di Certified Systems Integrator per i sistemi Universal Robots. Inoltre, Telescope ha dimostrato la produzione di carbonato di litio >99,5% puro utilizzando la sua tecnologia ReCRFT™ e sta costruendo un impianto pilota a Vancouver per gli studi di scalabilità.
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) reportó resultados financieros del Q1 FY2025 con ingresos de $1.2 millones, una disminución respecto a los $1.5 millones del Q1 FY2024. La empresa registró una pérdida de EBITA ajustada de $103,177, en comparación con las ganancias de $505,171 en el mismo período del año pasado. Los gastos aumentaron a $1.5 millones desde $1.3 millones en el año anterior.
Los aspectos operativos clave incluyen la entrega exitosa de productos DirectInject-LC™ bajo el acuerdo de distribución con Mettler Toledo, con demostraciones de productos en varios países. La empresa avanzó en su investigación de los Laboratorios Autónomos con Pfizer, logrando el estatus de Integrador de Sistemas Certificado para los sistemas de Robots Universales. Además, Telescope demostró la producción de carbonato de litio >99.5% puro utilizando su tecnología ReCRFT™ y está construyendo una planta piloto en Vancouver para estudios de escalado.
탐광 혁신 주식회사 (CSE: TELI) (OTCQB: TELIF)는 FY2025년 1분기 재무 결과를 보고하며 수익이 $1.2 백만으로 FY2024년 1분기의 $1.5 백만에서 감소했다고 발표했습니다. 이 회사는 지난해 같은 기간의 $505,171의 수익과 비교하여 조정된 EBITA 손실이 $103,177로 기록되었습니다. 경비는 작년의 $1.3 백만에서 $1.5 백만으로 증가했습니다.
주요 운영 하이라이트로는 Mettler Toledo 배급 계약에 따라 DirectInject-LC™ 제품의 성공적인 인도가 있으며, 여러 국가에서 제품 시연이 진행되었습니다. 이 회사는 Pfizer와 함께 자율 주행 연구를 진행하며 Universal Robots 시스템에 대한 인증 시스템 통합자 지위를 달성했습니다. 게다가 Telescope는 ReCRFT™ 기술을 사용하여 >99.5% 순수 리튬 탄산염 생산을 보여주었고, 밴쿠버에서 대규모 연구를 위한 파일럿 플랜트를 건설 중입니다.
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) a annoncé les résultats financiers du Q1 FY2025 avec des revenus de $1,2 million, en baisse par rapport à $1,5 million au Q1 FY2024. L'entreprise a enregistré une perte d'EBITA ajustée de $103,177, par rapport à un bénéfice de $505,171 pour la même période l'année précédente. Les dépenses ont augmenté à $1,5 million contre $1,3 million d'une année sur l'autre.
Les points saillants opérationnels clés incluent la livraison réussie des produits DirectInject-LC™ dans le cadre de l'accord de distribution avec Mettler Toledo, avec des démonstrations de produits dans plusieurs pays. L'entreprise a fait progresser ses recherches sur les Laboratoires Autonomes avec Pfizer, atteignant le statut d'Intégrateur de Systèmes Certifiés pour les systèmes Universal Robots. De plus, Telescope a démontré la production de carbonates de lithium >99,5% purs en utilisant sa technologie ReCRFT™ et construit une usine pilote à Vancouver pour des études d'échelle.
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) hat die finanziellen Ergebnisse des Q1 FY2025 mit Einnahmen von $1,2 Millionen bekannt gegeben, was einem Rückgang von $1,5 Millionen im Q1 FY2024 entspricht. Das Unternehmen verzeichnete einen ajustierten EBITA-Verlust von $103,177 im Vergleich zu einem Gewinn von $505,171 im selben Zeitraum des letzten Jahres. Die Ausgaben erhöhten sich auf $1,5 Millionen von $1,3 Millionen im Vorjahr.
Zu den wichtigsten operationellen Höhepunkten gehört die erfolgreiche Lieferung der DirectInject-LC™ Produkte im Rahmen des Vertriebsvertrags mit Mettler Toledo, mit Produktvorführungen in mehreren Ländern. Das Unternehmen hat seine Forschung in den Selbstfahrenden Laboren mit Pfizer vorangebracht und den Status als zertifizierter Systemintegrator für Universal Robots Systeme erreicht. Darüber hinaus hat Telescope die Produktion von >99,5% reinem Lithiumcarbonat mit seiner ReCRFT™ Technologie demonstriert und baut in Vancouver eine Pilotanlage für Skalierungsstudien.
- Successful delivery of DirectInject-LC™ products under global distribution agreement
- Geographic expansion with product demonstrations in US, Japan, Belgium, and Slovenia
- Achievement of Certified Systems Integrator status for Universal Robots systems
- Demonstration of >99.5% pure lithium carbonate production with ReCRFT™ technology
- Revenue decreased 20% YoY to $1.2M from $1.5M
- Expenses increased 20% YoY to $1.5M from $1.3M
- Adjusted EBITA loss of $103K compared to $505K earnings in previous year
Vancouver, British Columbia--(Newsfile Corp. - January 27, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal quarter ended November 30, 2024 (Q1). The Company generated revenues of
FINANCIAL HIGHLIGHTS OF THE FISCAL QUARTER ENDED NOVEMBER 30, 2024
All values are represented in CAD.
- Revenues of
$1,204,197 (versus$1,504,852 for the comparable period in FY 2024) - Expenses of
$1,547,734 (versus$1,289,852 for the comparable period in FY 2024) - Adjusted EBITA loss of
$103,177 (versus$505,171 earnings for the comparable period in FY 2024)
OPERATIONAL HIGHLIGHTS
FLAGSHIP PRODUCT DISTRIBUTION AND EXPANSION OF CUSTOMER BASE. Telescope successfully delivered all product orders under its multi-year global distribution agreement with Mettler Toledo for DirectInject-LC™. Product demonstrations in the US, Japan, Belgium, and Slovenia expanded market presence, while the Japan launch created immediate opportunities. Mettler Toledo also initiated a marketing campaign in November to further drive product adoption.
COLLABORATIVE RESEARCH WITH PFIZER ON SELF-DRIVING LABS. Under its multi-year agreement with Pfizer, Telescope advanced research activities to develop Self-Driving Laboratories (SDLs). Powered by artificial intelligence, advanced process analytical technology, and robotics, SDLs can accelerate pharmaceutical research and development by up to 100 times compared to traditional methods. Telescope also achieved Certified Systems Integrator (CSI) status for Universal Robots systems, enhancing its ability to deploy SDLs effectively, train clients on their use, and ensure seamless adoption of this transformative technology.
VALUE DEMONSTRATION OF IP FOR PRODUCING BATTERY RAW MATERIALS. The Company demonstrated production of over
99.5% pure lithium carbonate from Altillion brines using its proprietary ReCRFT™ technology, significantly reducing the costs and complexity of lithium refining. Telescope is now building a pilot plant in Vancouver to conduct scale-up engineering studies and demonstrate continuous operation to potential ReCRFT™ licensing customers. Telescope also published peer-reviewed research in Digital Discovery, showcasing how AI-driven optimization couples with ReCRFT™, achieving lithium carbonate yields exceeding83% and improving the sustainability of lithium processing.
"Our Q1 results position Telescope firmly on track to achieve our technical, strategic, and financial targets for the year," commented Henry Dubina, Telescope CEO. "The combination of strong product sales, groundbreaking collaborations such as our work with Pfizer on Self-Driving Labs, and the advancement of proprietary technologies such as ReCRFT™ highlights our ability to deliver value across multiple industries. As we continue to scale operations and reinvest in growth, we remain confident in our capacity to drive innovation and sustain our momentum throughout 2025."
Readers are encouraged to review the full financial statements and accompanying management discussion and analysis for the fiscal year ended November 30, 2024, both of which are available under the profile for the Company on SEDAR+ (www.sedarplus.ca).
About Telescope
Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.
On behalf of the Board,
Telescope Innovations Corp.
Henry Dubina, Chief Executive Officer
E: hdubina@telescopeinn.com
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238649
FAQ
What were Telescope Innovations (TELIF) Q1 2025 revenue and earnings?
How did TELIF's Q1 2025 financial results compare to Q1 2024?
What progress did TELIF make with its DirectInject-LC product in Q1 2025?
What advancement did TELIF achieve in lithium production technology?
